CONTEXT: Report from the American Academy of Neurology on Biogen’s main two MS compounds, with RWE showing value on detecting patient QoL and overall treatment preferences.
READ TIME: 2 mins
Quality Level Mean [1 – 10]: 5
1. ““These data show that the benefits TYSABRI provides in terms of a patient’s quality of life are substantial and that the positive gastrointestinal tolerability profile of VUMERITY can help people with relapsing MS continue with treatment, which is essential to delay its progression.””
2. “New findings from MS PATHS show that treatment with TYSABRI® (natalizumab) can lead to meaningful improvements in mental and social health compared to Ocrevus® (ocrelizumab). Real-world data from VUMERITY® (diroximel fumarate) reinforce the treatment’s positive gastrointestinal tolerability profile . Biogen advances leading research to help inform future patient management including new information on the clinical profile of extended interval dosing with natalizumab. CAMBRIDGE, Mass., April 16, 2021 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced new data from its industry-leading portfolio of multiple sclerosis (MS) therapies to be presented at the American Academy of Neurology (AAN) 2021 Virtual Annual Meeting, April 17-22.”
3. “The presentations include data on quality of life benefits and analyses of extended interval dosing (EID) with TYSABRI® (natalizumab) as well as new real-world experience data from VUMERITY® (diroximel fumarate).”
4. “Analyses Demonstrate Improved Quality of Life Outcomes with TYSABRI and Further Evaluate Extended Interval Dosing . To better understand clinically meaningful quality of life benefits following treatment with TYSABRI, MS PATHS (Partners Advancing Technology and Health Solutions) researchers analyzed patient reported data on 12 different domains on the Neuro-QoL (Quality of Life in Neurological Disorders) questionnaire such as sleep disturbance, anxiety, fatigue, depression and participation in daily activities.”
5. “Biogen currently has more than 25 MS clinical trials underway including research on considerations around COVID-19 vaccination for people with MS.. Data Presentations Featured at AAN:. Impact of Natalizumab on Quality of Life in a Real-World Cohort of Patients with Multiple Sclerosis: Results from MS Partners Advancing Technology and Health Solutions (MS PATHS) – P15.023. No Difference in Radiologic Outcomes for Natalizumab Patients on Extended Interval Dosing Compared with Standard Interval Dosing in MS PATHS – P15.210. Natalizumab Extended Interval Dosing (EID) is Associated with a Reduced Risk of Progressive Multifocal Leukoencephalopathy (PML) Compared with Every-4-week (Q4W) Dosing: Updated Analysis of the TOUCH® Prescribing Program Database – P15.201. Multiple Sclerosis Patients Treated with Diroximel Fumarate in the Real-world Setting have High Rates of Persistence and Adherence – P15.227. About TYSABRI® (natalizumab) . TYSABRI is a well-established relapsing multiple sclerosis (RMS) treatment indicated for relapsing forms of MS in adults that has been proven in clinical trials to slow physical disability progression, reduce the formation of new brain lesions and cut relapses.”
Source URL: https://finance.yahoo.com/news/data-aan-2021-across-biogen-113000321.html